Search

Displaying results 1721 - 1730 of 10000 in total
  1. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Chlorothiazide

    go.drugbank.com/drugs/DB00880
    ApprovedInvestigationalVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

  3. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.

  4. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.

    Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer Fertigspritze
  5. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.

  6. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  7. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.

  8. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin. … In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

  10. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … prescribed in South America.